• Diego SerrainoEmail author
  • Luigino Dal Maso


This chapter addresses epidemiological aspects of HIV-associated hematological malignancies in the combination antiretroviral therapy (cART) era. Before the advent of cART, people with HIV infection or AIDS (PWA) had several hundredfold higher risk of non-Hodgkin’s lymphoma (NHL) and about 10- to 20-fold higher risk of Hodgkin’s lymphoma (HL) than the general population of the same sex and age. Although the incidence of NHL in PWA has fallen markedly in the cART era, it remains remarkably higher than in the general population, while rates and excesses of HL remain substantially unvaried. By contrast, leukemias, multiple myeloma, and other hematological conditions are only slightly more common in HIV settings. In addition to a higher risk of developing hematological malignancies, PWA are also at elevated risk of death than their counterparts in the general population. A persisting, although narrowing, gap in cancer survival between PWA and non-PWA is still observed.


Standardize Mortality Ratio Plasma Cell Neoplasm Immunoblastic Lymphoma Nodular Sclerosis Type Receive mTOR Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96.CrossRefGoogle Scholar
  2. 2.
    Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300:51–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Biggar RJ, Engels E, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Carrieri MP, Pradier C, Piselli P, Piche M, Rosenthal E, Heudier P, et al. Reduced incidence of Kaposi’s sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer. 2003;103:142–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010;24:1765–70.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood. 2009;113:5737–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33:2376–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Dal Maso L, Rezza G, Zambon P, Tagliabue G, Crocetti E, Vercelli M, et al. Non-Hodgkin lymphoma among young adults with and without AIDS in Italy. Int J Cancer. 2001;93:430–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphoma and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. 2003;4:110–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer. 2009;100:840–7.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Dal Maso L, Suligoi B, Franceschi S, Braga C, Buzzoni C, Polesel J, et al. Survival after cancer in Italian persons with AIDS, 1986–2005: a population-based estimation. J Acquir Immune Defic Syndr. 2014;66:428–35.CrossRefGoogle Scholar
  12. 12.
    Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS. 2010;24:1537–48.Google Scholar
  13. 13.
    Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Frisch M, Biggar RJ, Engels EA, Goedert JJ, for the AIDS Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28:2313–8.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Temporal Trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105:1221–9.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients a meta-analysis. Lancet. 2007;370:59–67.CrossRefPubMedGoogle Scholar
  20. 20.
    Harrison KMD, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 States, United States. J Acquir Immune Defic Syndr. 2010;53:124–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J, et al. Causes of death among Danish HIV patients compared with population controls in the period 1995–2008. Infection. 2012;40:627–34.CrossRefPubMedGoogle Scholar
  22. 22.
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100B. A Review of human carcinogenesis. IARC Monogr Eval Carcinog Risks Hum. 2012;100(pt B):1–441.Google Scholar
  23. 23.
    Krishnan A, Palmer JM, Zaia JA, Tsai NC, Alvarnas J, Forman SJ. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant. 2010;16:1302–8.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” survey (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23:1743–53.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973–2004. J Neurooncol. 2011;101:487–93.CrossRefPubMedGoogle Scholar
  28. 28.
    Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer. 2013;49:336–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, et al. Non-Hodgkin’s lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2008;22:301–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Polesel J, Franceschi S, Suligoi B, Crocetti E, Falcini F, Guzzinati S, et al. Cancer incidence in people with AIDS. Int J Cancer. 2010;127:1437–45.CrossRefPubMedGoogle Scholar
  31. 31.
    Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C, Ocular Complications of AIDS Research Group. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis. 2010;51:947–56.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015;107(4):dju503.CrossRefPubMedGoogle Scholar
  33. 33.
    Serraino D, Carbone A, Franceschi S, Tirelli U. Increased frequency of lymphocyte depletion and mixed cellularity subtypes of Hodgkin’s disease in HIV-infected patients. Italian Cooperative Group on AIDS and Tumours. Eur J Cancer. 1993;29A:1948–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43:2117–23.CrossRefPubMedGoogle Scholar
  35. 35.
    Serraino D, De Paoli A, Zucchetto A, Pennazza S, Bruzzone S, Spina M, et al. The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. Cancer Epidemiol. 2010;34:257–61.CrossRefPubMedGoogle Scholar
  36. 36.
    Serraino D, Pezzotti P, Dorrucci M, Alliegro MB, Sinicco A, Rezza G. Cancer incidence in a cohort of human immunodeficiency virus seroconverters. HIV Italian Seroconversion Study Group. Cancer. 1997;79:1004–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, et al. Survival after AIDS diagnosis in Italy, 1999–2006: a population-based study. J Acquir Immune Defic Syndr. 2009;52:99–105.CrossRefPubMedGoogle Scholar
  38. 38.
    Shiels MS, Engels EA, Linet MS, Clarke CA, Li J, Hall HI, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992–2009. Cancer Epidemiol Biomarkers Prev. 2013;22:1069–78.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Shiels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23:274–81.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51:957–62.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Spagnuolo V, Travi G, Galli L, Cossarini F, Guffanti M, Gianotti N, et al. Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. Cancer. 2013;119:2710–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS. 2009;23:2183–90.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Zucchetto A, Suligoi B, De Paoli A, et al. Excess mortality for non- AIDS-defining cancers among people with AIDS. Clin Infect Dis. 2010;51:1099–101.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Unit of Epidemiology and BiostatisticsCRO Aviano National Cancer Institute, IRCCSAvianoItaly

Personalised recommendations